The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single cell characterization of persistent cells upon immunotherapy treatment in colorectal and endometrial tumors: The SERPENTINE trial.
 
Iosune Baraibar
Travel, Accommodations, Expenses - Amgen; Merck; SERVIER
 
Carmen García Durán
Speakers' Bureau - Clovis Oncology; MSD/AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
 
Paula Nieto
No Relationships to Disclose
 
Juan Francisco Grau Béjar
No Relationships to Disclose
 
Gerard Deuner
No Relationships to Disclose
 
David García-Illescas
Honoraria - GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca/Merck; GlaxoSmithKline; Merck
Other Relationship - AstraZeneca (Inst); Eisai (Inst)
 
Ginevra Caratu
No Relationships to Disclose
 
Lorena Fariñas-Madrid
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca Spain; GlaxoSmithKline; MSD Oncology
 
Miren Berasategi
No Relationships to Disclose
 
Marta Grzelak
Employment - Omniscope
 
Asaf Rotem
Employment - AstraZeneca
 
Juan Luis Melero
Employment - Omniscope
 
Patricia Casbas-Hernandez
Employment - AstraZeneca
 
Nick Borcherding
No Relationships to Disclose
 
Juan Nieto
No Relationships to Disclose
 
Alena Gros
No Relationships to Disclose
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; AVEO; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Immodulon Therapeutics; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OneXerna Therapeutics, Inc.; PharmaMar; Regeneron; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Zentalis
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Holger Heyn
Leadership - MiRXES; NanoString Technologies
Consulting or Advisory Role - Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Omniscope